Home Merck

Merck

Merck Receives Complete Response Letter from the U.S. FDA for TECOS Study with Sitagliptin

April 7, 2017: Complete Response Letter regarding Merck’s Supplemental New Drug Applications for JANUVIA® (sitagliptin), JANUMET® (sitagliptin...